Myasthenia gravis (MG) is an antibody-mediated disorder of the neuromuscular junction (NMJ) that causes fatigable weakness. This simple pathology-focused guide explains how autoantibodies impair transmission, why clinical weakness fluctuates, and which investigations and therapies follow from the underlying mechanism.
🔄 Quick Overview
MG is most often caused by autoantibodies against postsynaptic proteins (acetylcholine receptor — AChR, or muscle-specific kinase — MuSK). Antibody binding reduces effective AChR number and disrupts synaptic structure, producing fatigable muscle weakness that worsens with use and improves with rest.
Core facts
- Autoimmune attack at the NMJ → decreased safety margin of neuromuscular transmission.
- Typical presentation: ocular (ptosis, diplopia), bulbar (dysarthria, dysphagia), and generalized fatigable weakness.
- Associations: thymic hyperplasia/thymoma in many patients; paraneoplastic forms exist.
Why pathology matters
- Understanding target antigen (AChR vs MuSK vs LRP4) guides testing and predicts treatment response.
- Thymic pathology (hyperplasia or thymoma) influences decision for thymectomy.
🧬 Pathophysiology — How the NMJ Fails
Keep the sequence simple: autoantibodies bind → receptor loss / complement-mediated damage / postsynaptic structural change → reduced endplate potentials → failure of muscle contraction with sustained activity.
AChR antibody–positive MG
- Autoantibodies (IgG1/3) bind AChR, fix complement → postsynaptic membrane damage and AChR internalization.
- Leads to reduced receptor density and simplified endplate morphology on electron microscopy.
MuSK / LRP4 antibody MG
- MuSK antibodies (often IgG4) disrupt agrin–MuSK signaling → disorganized postsynaptic architecture and poor AChR clustering.
- Clinical phenotype often has more bulbar/respiratory involvement and different treatment responses.
Thymic role
- Thymic hyperplasia with germinal centers is common in early-onset AChR-MG and may drive autoantibody production.
- Thymoma-associated MG reflects paraneoplastic autoimmunity and often requires thymoma resection.
🔍 Clinical Patterns & Pathologic Correlates
Symptoms reflect fatigability and which muscle groups are affected — link phenotype to likely pathology.
Ocular MG
- Isolated ptosis and diplopia; often AChR antibodies detectable in many but not all cases.
Generalized MG
- Proximal limb weakness, bulbar dysfunction, respiratory muscle involvement; severity varies and may fluctuate diurnally.
Myasthenic crisis
- Life-threatening respiratory failure from NMJ failure — pathology-driven treatments (plasmapheresis/IVIG) rapidly lower pathogenic antibody load.
🔬 Diagnosis: Antibodies, Electrophysiology, and Thymic Imaging
Diagnosis combines serologic markers, neurophysiology (repetitive nerve stimulation, single-fiber EMG), and imaging of the thymus.
| Test | Role / What it shows |
|---|---|
| Serology | AChR antibodies positive in ~80–85% generalized MG; MuSK antibodies in a subset (often seronegative for AChR); LRP4 and other antibodies in some cases. |
| Electrophysiology | Repetitive nerve stimulation shows decremental response; single-fiber EMG demonstrates increased jitter — both indicate impaired neuromuscular transmission. |
| Ice test / edrophonium | Ancillary bedside tests: ice test may transiently improve ptosis; edrophonium historically used but less common now. |
| Chest imaging | CT/MRI of the mediastinum evaluates thymic hyperplasia or thymoma—important for surgical planning. |
🎯 Management & Treatment (Pathology-driven)
Therapy targets symptoms (improve transmission), reduces pathogenic antibody production, and removes thymic sources when indicated. Choice depends on antibody type, thymic pathology, and disease severity.
Symptomatic & rapid-acting
- Acetylcholinesterase inhibitors (pyridostigmine) increase ACh at the NMJ and improve strength acutely.
- Plasmapheresis or IVIG used for myasthenic crisis or preoperative optimization to remove circulating antibodies quickly.
Immunomodulatory & disease-modifying
- Long-term immunosuppression (steroids, steroid-sparing agents like azathioprine, mycophenolate) reduces antibody production.
- Thymectomy indicated in many AChR-antibody positive patients (especially thymoma or early-onset generalized MG) — thymic pathology guides decision.
- Targeted biologics (e.g., complement inhibitors, FcRn blockers) are used in refractory cases based on underlying antibody mechanisms.
⚠️ Complications & Prognosis
Prognosis has improved markedly with modern therapies; outcomes depend on severity, antibody type, thymic disease, and access to care.
- Myasthenic crisis (respiratory failure) is the most serious acute complication.
- Chronic bulbar weakness predisposes to aspiration and nutritional problems.
- Thymoma-associated MG requires oncologic and neurologic coordination; removal can be curative for thymoma but MG may persist.
🧠 Key Takeaways
- MG is an antibody-mediated failure of the NMJ causing fatigable weakness; AChR and MuSK are principal targets.
- Pathologic markers (antibodies, thymic histology) guide diagnosis and therapy — thymectomy for thymoma/hyperplasia, plasmapheresis/IVIG for crises, immunosuppression for long-term control.
- Electrophysiology (repetitive stimulation, single-fiber EMG) and targeted antibody testing confirm diagnosis when clinical suspicion is high.
- Recognize myasthenic crisis early — pathology-directed rapid therapy and respiratory support are lifesaving.
🧭 Conclusion
Myasthenia gravis is a clear example of pathology directly shaping treatment: identify the antibody, evaluate the thymus, and match symptomatic, rapid-acting and immunomodulatory therapies to disease stage. Understanding the NMJ pathology makes clinical decisions straightforward and improves patient outcomes.
Bottom line: Autoantibodies break the neuromuscular junction — test for antigen specificity, image the thymus, treat crises urgently, and use immunomodulation and thymectomy guided by pathology.